文献速递浆细胞疾病

多发性骨髓瘤真实世界一线治疗模式的演变

Evolution of real-world frontline treatment patterns in multiple myeloma.
PubMed 文献 · Blood Adv · 2026-01-01

研究发现尽管医疗可及性平等,以区域剥夺指数衡量的较低社会经济地位仍与死亡率增加独立相关,且各治疗时代结局持续改善但近期队列随访有限。

要点

  • 在医疗可及性平等的退伍军人事务部系统中,较低社会经济地位仍与死亡率增加独立相关。
  • 过去二十年多发性骨髓瘤治疗选择日益复杂,新药在临床实践中的采纳存在差异。
  • 各治疗时代的生存结局持续改善,但近期队列随访时间有限,长期生存尚未完全明确。

核心结论

  • 尽管医疗可及性平等,较低社会经济地位仍与多发性骨髓瘤患者死亡率增加独立相关。
  • 各治疗时代的生存结局持续改善,但近期队列随访有限,长期生存尚未完全明确。
  • 需要实施策略解决影响多发性骨髓瘤最佳照护的结构性和社会性障碍。

研究设计与样本

  • 在医疗可及性平等的背景下分析不同治疗方案的总体生存,并按诊断时代和社会人口学特征分层。

主要发现

  • 各治疗时代的结局持续改善,但近期队列随访有限。
  • 以区域剥夺指数近似的较低社会经济地位与死亡率增加独立相关,尽管医疗可及性平等。

关键数值与推荐

  • 以区域剥夺指数近似社会经济地位,较低水平与死亡率增加独立相关。

临床怎么用

  • 临床实践中应关注多发性骨髓瘤患者的社会经济因素,并采取措施解决结构性障碍以优化照护。

局限性

  • 近期队列随访时间有限,长期生存尚未完全明确。
  • 随机临床试验排除老年、医学复杂和社会经济弱势患者,限制其结论在真实世界的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The number of Food and Drug Administration-approved treatments for multiple myeloma (MM), the second most common hematologic malignant neoplasm, has increased substantially over the past 2 decades. Treatment decisions have become more complex over time, and there is variable adoption of new agents in clinical practice. Survival trends have improved with novel therapies; however, these trends are not equitably distributed across patient populations. Although randomized clinical trials have guide treatment strategies, their exclusion of older, medically complex, and socioeconomically disadvantaged patients limits applicability to real-world outcomes. Understanding the natural history of MM and how treatment patterns have changed over time is essential for informing optimal MM care in clinical practice. We retrospectively evaluated 20 135 patients with newly diagnosed MM from the national Veterans Affairs (VA) health system between 2000 and 2024. The VA offers a unique setting to study these patterns in the equal-access context, in which cost is less of a factor, allowing us to assess trends in treatment decisions and outcomes across diverse strata. We analyzed overall survival by treatment regimen, diagnosis era, and sociodemographic features. Lower socioeconomic status as approximated by the area deprivation index was independently associated with increased mortality despite equal health care access. Outcomes continue to improve across treatment eras, although follow-up in the most recent cohort is limited and long-term survival remains incompletely characterized. These findings underscore the need for implementing strategies to address the structural and social barriers to optimal MM care.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lazzaro A, Nannini K, Yildirim C, et al. Evolution of real-world frontline treatment patterns in multiple myeloma. Blood Adv. 2026. PMID: 42480210. doi:10.1182/bloodadvances.2026019843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。